share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)

SEC announcement ·  Apr 23 15:00
Summary by Moomoo AI
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more